0001415889-23-003854.txt : 20230302 0001415889-23-003854.hdr.sgml : 20230302 20230302170445 ACCESSION NUMBER: 0001415889-23-003854 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reents Scott T CENTRAL INDEX KEY: 0001937048 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 23700148 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-03022023_100328.xml X0306 4 2023-02-28 0001551152 AbbVie Inc. ABBV 0001937048 Reents Scott T 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF FINANCIAL OFFICER Common Stock, $0.01 par value 2023-02-28 4 F 0 12683 154.28 D 16751 D Common Stock, $0.01 par value 2023-03-01 4 S 0 15092 153.06 D 1659 D Common Stock, $0.01 par value 2023-03-01 4 S 0 850 153.38 D 809 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $153.47, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Steven L. Scrogham, attorney-in-fact for Scott T. Reents 2023-03-02